Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S H Fox

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Biochemical and Biophysical Research Communications|July 12, 1976
Thyroxine-binding globulin synthesis by hepatocarcinoma cells in continuous culture: effect of physiological concentrations of thyroxineM C Gershengorn, D Glinoer, S H Fox, et al.
Journal of the American Academy of Dermatology|December 1, 1990
The risk of developing subsequent nonmelanoma skin cancersM M Schreiber, T E Moon, S H Fox, et al.
Experimental Neurology|August 25, 2001
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's diseaseB Henry, S H Fox, A R Crossman, et al.
Public Health Reports (Washington, D.C. : 1974)|January 1, 1987
Perceptions of risks of smoking and heavy drinking during pregnancy: 1985 NHIS findingsS H Fox, C Brown, A M Koontz, et al.
Radiology|February 7, 2001
Four multidetector-row helical CT: image quality and volume coverage speedH Hu, H D He, W D Foley, et al.
Brain, Behavior and Evolution|January 1, 1994
GnRH cell size and number in a teleost fish with two male reproductive morphs: sexual maturation, final sexual status and body size allometryM S Grober, S H Fox, C Laughlin, et al.
Advances in Neurology|November 22, 2002
Potential nondopaminergic drugs for Parkinson's diseaseMonty A Silverdale, S H Fox, A R Crossman, et al.
Neurology|August 19, 2007
Isolated diaphragmatic tremor: is there a spectrum in "respiratory myoclonus"?A J Espay, S H Fox, C Marras, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 24, 1999
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's diseaseB Henry, S H Fox, D Peggs, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|December 8, 2007
Clinical practice regarding dopamine-agonist use and driving in Parkinson's diseaseR M A de Bie, J Miyasaki, A E Lang, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Biochemical and Biophysical Research Communications|July 12, 1976
Thyroxine-binding globulin synthesis by hepatocarcinoma cells in continuous culture: effect of physiological concentrations of thyroxineM C Gershengorn, D Glinoer, S H Fox, et al.
Journal of the American Academy of Dermatology|December 1, 1990
The risk of developing subsequent nonmelanoma skin cancersM M Schreiber, T E Moon, S H Fox, et al.
Experimental Neurology|August 25, 2001
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's diseaseB Henry, S H Fox, A R Crossman, et al.
Public Health Reports (Washington, D.C. : 1974)|January 1, 1987
Perceptions of risks of smoking and heavy drinking during pregnancy: 1985 NHIS findingsS H Fox, C Brown, A M Koontz, et al.
Radiology|February 7, 2001
Four multidetector-row helical CT: image quality and volume coverage speedH Hu, H D He, W D Foley, et al.
Brain, Behavior and Evolution|January 1, 1994
GnRH cell size and number in a teleost fish with two male reproductive morphs: sexual maturation, final sexual status and body size allometryM S Grober, S H Fox, C Laughlin, et al.
Advances in Neurology|November 22, 2002
Potential nondopaminergic drugs for Parkinson's diseaseMonty A Silverdale, S H Fox, A R Crossman, et al.
Neurology|August 19, 2007
Isolated diaphragmatic tremor: is there a spectrum in "respiratory myoclonus"?A J Espay, S H Fox, C Marras, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 24, 1999
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's diseaseB Henry, S H Fox, D Peggs, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|December 8, 2007
Clinical practice regarding dopamine-agonist use and driving in Parkinson's diseaseR M A de Bie, J Miyasaki, A E Lang, et al.
Pageof 6